Securities code: 688317 securities abbreviation: Shanghai Zj Bio-Tech Co.Ltd(688317) Announcement No.: 2022-010 Shanghai Zj Bio-Tech Co.Ltd(688317)
Suggestive announcement on the change of equity of Ningbo ruidao venture capital partnership (limited partnership), a shareholder holding more than 5%
The board of directors, all directors and relevant shareholders of the company guarantee that there are no false records, misleading statements or major omissions in the contents of the announcement, and bear legal responsibility for the authenticity, accuracy and integrity of its contents in accordance with the law.
Important content tips:
This acquisition does not involve the change of equity;
After this equity change, Ningbo ruidao venture capital partnership (limited partnership) (hereinafter referred to as "Ningbo ruidao" or "information disclosure obligor") holds 9735018 shares of Shanghai Zj Bio-Tech Co.Ltd(688317) (hereinafter referred to as "the company"), accounting for 4.99% of the total shares of the company;
Ningbo ruidao is not the controlling shareholder of the company. This equity change will not lead to the change of the controlling shareholder and actual controller of the company.
On February 16, 2022, the company received the short form equity change report issued by the shareholder Ningbo ruidao, and now announces its relevant equity changes as follows:
1、 Changes in equity this time
(I) basic information of information disclosure obligor
As of the disclosure date of this announcement, the basic information of information disclosure obligors is as follows:
Enterprise name: Ningbo ruidao venture capital partnership (limited partnership)
Type of enterprise: limited partnership
Registered address: c0363, zone B, Room 401, building 1, No. 88, Meishan Qixing Road, Beilun District, Ningbo City, Zhejiang Province
Date of establishment: October 9, 2010
Operation period: October 8, 2030
Executive partner Ji Chengwei
Ji Chengwei, the representative appointed by the executive partner
Unified social credit code 913302065630057537
Business scope venture capital (limited to investment in unlisted companies). [for projects subject to approval according to law, business activities can be carried out only after approval by relevant departments]
Mailing address: c0363, zone B, Room 401, building 1, No. 88, Qixing Road, Meishan, Beilun District, Ningbo, Zhejiang
Major partners and capital contributions:
Subscribed capital contribution subscribed capital contribution ratio serial number partner name
(10000 yuan) case (%)
1 Ji Chengwei 473.4 5.26
2 Wang Neng 947.7 10.53
Chapter 3 Junhui 315.9 3.51
4 Chen Mei 315.9 3.51
5 Sun Lihua 552.6 6.14
6 Zhang Ying 315.9 3.51
7 Xu Manping 158.4 1.76
8 Ni Yuhua 315.9 3.51
9 Ding Xiaomei 474.3 5.27
10 Deng Jianhua 205.2 2.28
11 Qiu Jianyi 236.7 2.63
12 Zhang Huiyan 711 7.9
13 Lujie 347.4 3.86
14 Peng Jianmin 315.9 3.51
15 Ye Feng 789.3 8.77
16 Wang binyuan 315.9 3.51
17 Shen Yu 395.1 4.39
18.395.1 4.39
19 Zhang Ying 144 1.6
20 Wu Xiaoling 360 4
21 Xu Ying 914.4 10.16
Total - 9000 100
Note: the discrepancy between the total and the mantissa of the sum of the sub item values is caused by rounding.
(II) changes in equity
In this equity change, the details of the equity change of the information disclosure obligor are as follows:
Price range in total share capital shareholder name reduction method change time reduction number of shares (shares)
(yuan / share) ratio
Ningbo ruidao block trading 2022.2.9 32.64 73000 0.04%
Ningbo ruidao block trading 2022.2.10 33.10 65000 0.03%
Ningbo ruidao centralized bidding transaction 2022.2.15 37.01 518439 0.27%
Ningbo ruidao centralized bidding transaction 2022.2.16 37.18 423343 0.22%
Total / / 1079782 0.56%
remarks:
1. All the shares involved in this equity change enjoy voting rights, and there are no restrictions on the transfer of voting rights, such as delegation or restriction of voting rights.
2. This change does not violate the securities law of the people's Republic of China, the measures for the administration of the acquisition of listed companies and other laws and regulations, the business rules of Shanghai Stock Exchange and other relevant provisions and relevant commitments.
2、 Before and after this equity change, the information discloser's shares in the company's equity
Shares held before this change name of shareholders holding shares after this change nature of shares holding quantity of shares holding quantity of shares
Shareholding ratio shareholding ratio (share) (share)
Ningbo ruidao
Unlimited sales of venture capital
10,814,800 5.55% 9,735,018 4.99%
Circulating shares of partnership (limited partnership)
(partner)
remarks:
All the shares of the company held by the information disclosure obligor after this equity change enjoy voting rights, and there are no rights restrictions or restricted transfers such as voting rights entrustment or restriction.
3、 Follow up matters involved
1. This equity change is a reduction of holdings and does not touch the tender offer.
2. According to the provisions of laws, regulations and normative documents such as the securities law of the people's Republic of China, the measures for the administration of the acquisition of listed companies and the standards for the contents and forms of information disclosure by companies offering securities to the public No. 15 - Report on changes in equity, this change in equity involves the disclosure of a simplified report on changes in equity by the information disclosure obligor, For details, please refer to the website of Shanghai Stock Exchange on the same day (www.sse. Com. CN.) The Shanghai Zj Bio-Tech Co.Ltd(688317) simplified equity change report disclosed.
3. This equity change is the normal reduction of shareholders' holdings and will not have a significant impact on the corporate governance structure and sustainable operation. This equity change will not lead to the change of controlling shareholders and actual controllers.
4. After this equity change, the information disclosure obligor is still in the reduction period. The company will urge it to strictly implement the relevant provisions on reducing its holdings and disclose relevant information to investors in time. Please pay attention to investment risks. It is hereby announced.
Shanghai Zj Bio-Tech Co.Ltd(688317) board of directors February 17, 2022
